急诊老年急性心衰早期综合管理集束化方案:ELISABETH阶梯楔形整群随机试验方案
ELISABETH为法国15个急诊科的阶梯楔形整群随机对照试验,纳入75岁及以上急性心衰(AHF)患者,评价包含早期识别并处理诱因、静脉硝酸酯类积极缓解淤血及低剂量利尿剂等推荐治疗的集束化方案能否改善预后。主要终点为30天存活且未住院天数,所有中心最终均进入干预期。
要点
- 纳入75岁及以上急诊AHF患者,干预为早期综合集束化方案。
- 主要终点为30天存活且未住院天数。
- 采用阶梯楔形整群随机设计,15个急诊科依次从对照期转入干预期。
核心结论
- 若假设成立,该试验将强化AHF指南的证据水平,并强调早期综合处理诱因的重要性。
研究设计与样本
- ELISABETH为阶梯楔形整群随机对照临床试验,在法国15个急诊科开展,纳入所有75岁及以上诊断为AHF的患者。
主要发现
- 原文未报告试验结果。
关键数值与推荐
- 干预为集束化方案加核查表,要求检测并早期治疗AHF诱因、静脉硝酸酯类弹丸注射早期强化治疗淤血,以及应用低剂量利尿剂、有指征时无创通气、预防性低分子肝素等推荐治疗。
- 主要终点为30天存活且未住院天数。
- 各中心先进入2周对照期,此后每2周一个新中心进入干预期,试验结束时所有集群均接受干预。
临床怎么用
- 该方案尚在试验阶段,临床实践应等待试验结果后再考虑推广。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute heart failure (AHF) is one of the most common diagnoses for elderly patients in the emergency department (ED), with an admission rate above 80% and 1-month mortality around 10%. The European guidelines for the management of AHF are based on moderate levels of evidence, due to the lack of randomized controlled trials and the scarce evidence of any clinical added value of a specific treatment to improve outcomes. Recent reports suggest that the very early administration of full recommended therapy may decrease mortality. However, several studies have highlighted that elderly patients often received suboptimal treatment. Our hypothesis is that an early care bundle that comprises early and comprehensive management of symptoms, along with prompt detection and treatment of precipitating factors should improve AHF outcome in elderly patients. METHODS/DESIGN: ELISABETH is a stepped-wedge, cluster randomized controlled, clinical trial in 15 emergency departments in France recruiting all patients aged 75 years and older with a diagnosis of AHF. The tested intervention is a care bundle with a checklist that mandates detection and early treatment of AHF precipitating factors, early and intensive treatment of congestion with intravenously administered nitrate boluses, and application of other recommended treatment (low-dose diuretics, non-invasive ventilation when indicated, and preventive low-molecular-weight heparin). Each center is randomized to the order in which they will switch from a "control period" to an "intervention period." All centers begin the trials with the control period for 2 weeks, then after each 2-week step a new center will enter the intervention period. At the end of the trial, all clusters will receive the intervention regimen. The primary outcome is the number of days alive and out of the hospital at 30 days. DISCUSSION: If our hypothesis is confirmed, this trial will strengthen the level of evidence of AHF guidelines and stress the importance of the associated early and comprehensive treatment of precipitating factors. This trial could be the first to report a reduction in short-term morbidity and mortality in elderly AHF patients. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT03683212. Prospectively registered on 25 September 2018.
引用
- Freund Y, Gorlicki J, Cachanado M, et al. Early and comprehensive care bundle in the elderly for acute heart failure in the emergency department: study protocol of the ELISABETH stepped-wedge cluster randomized trial. Trials. 2019. PMID: 30704508. doi:10.1186/s13063-019-3188-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。